ReviewInternal medicine journal2026
Driving in hepatic encephalopathy.
Review in Internal medicine journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is a reversible neuropsychiatric complication of cirrhosis associated with cognitive and psychomotor impairment that may compromise driving safety. Deficits in attention, visuospatial ability, reaction time and executive function contribute to impaired on-road performance and increased motor vehicle collision rates. Despite this, there are no standardised Australian guidelines addressing driving in patients with HE, and international guidelines remain heterogenous. This article reviews the impact of overt (OHE) and covert HE on driving performance and outlines a pragmatic, risk-stratified framework. For patients with prior OHE, our approach is a time-limited driving restrictions based risk assessment, with conditional return to driving following sustained clinical stability and adherence to therapy. This framework aims to balance public safety with preservation of patient autonomy and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.